ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för (2R,6R)-6-hydroxynorketamine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2025-05-21

Bioactive ketamine metabolite exerts in vivo neuroplastogenic effects to improve hippocampal function in a treatment-resistant depression model.

Riggs LM, Aronson S, Mou TM, Pereira EFR, Thompson SM, Gould TD.

Cell Rep · research-article; journal article · DOI 10.1016/j.celrep.2025.115743

Bibliografisk träff 2025-04-08

The antidepressant potential of (2R,6R)-hydroxynorketamine: A detailed review of pre-clinical findings.

Koutrouli I, Mazochová K, Horsley RR.

Eur J Pharmacol · review; journal article · DOI 10.1016/j.ejphar.2025.177604

Bibliografisk träff 2025-03-28

(2R,6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement in mice.

Michael A, Onisiforou A, Georgiou P, Koumas M, Powels C, Mammadov E, Georgiou AN, Zanos P.

Br J Pharmacol · journal article · DOI 10.1111/bph.70018

Bibliografisk träff 2025-03-17

Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity.

Brown KA, Ajibola MI, Gould TD.

Neuropsychopharmacology · research-article; journal article · DOI 10.1038/s41386-025-02085-4

Bibliografisk träff 2025-02-08

(2R, 6R)-hydroxynorketamine alleviates postictal depression induced by pilocarpine through modulating LRP4 expression in hippocampal astrocytes.

Zhang M, Zheng L, Chen J, Yu Z.

Epilepsy Behav · journal article · DOI 10.1016/j.yebeh.2025.110294

Bibliografisk träff 2024-10-05

(2R,6R)-hydroxynorketamine alleviates PTSD-like endophenotypes by regulating the PI3K/AKT signaling pathway in rats.

Liu L, Li R, Wu L, Guan Y, Miao M, Wang Y, Li C, Wu C, Lu G, Hu X, Sun L.

Pharmacol Biochem Behav · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pbb.2024.173891

Bibliografisk träff 2024-09-24

(2R, 6R)-hydroxynorketamine ameliorates PTSD-like behaviors during the reconsolidation phase of fear memory in rats by modulating the VGF/BDNF/GluA1 signaling pathway in the hippocampus.

Wang H, He Y, Tang J, Liu Y, Wu C, Li C, Sun H, Sun L.

Behav Brain Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbr.2024.115273

Bibliografisk träff 2024-07-25

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.

Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, Jordan L, Rich N, Castledine R, Bourne S, Wilmshurst M, Oxendine S, Avula SGC, Zuleta H, Quigley P, Lawson S, McQuaker SJ, Ahmadkhaniha R, Appelbaum LG, Kowalski K, Barksdale CT, Gufford BT, Awan A, Sancho AR, Moore MC, Berrada K, Cogan GB, DeLaRosa J, Radcliffe J, Pao M, Kennedy M, Lawrence Q, Goldfeder L, Amanfo L, Zanos P, Gilbert JR, Morris PJ, Moaddel R, Gould TD, Zarate CA, Thomas CJ.

Clin Pharmacol Ther · research support, n.i.h., intramural; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/cpt.3391

Bibliografisk träff 2024-07-14

Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.

Loan Nguyen TM, Guilloux JP, Defaix C, Mendez-David I, Etting I, Alvarez JC, McGowan JC, Highland JN, Zanos P, Lovett J, Moaddel R, Corruble E, David DJ, Gould TD, Denny CA, Gardier AM.

Neuropharmacology · research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.neuropharm.2024.110065

Bibliografisk träff 2024-06-27

The ketamine metabolite (2R,6R)-hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer's disease.

Ribeiro FC, Cozachenco D, Argyrousi EK, Staniszewski A, Wiebe S, Calixtro JD, Soares-Neto R, Al-Chami A, Sayegh FE, Bermudez S, Arsenault E, Cossenza M, Lacaille JC, Nader K, Sun H, De Felice FG, Lourenco MV, Arancio O, Aguilar-Valles A, Sonenberg N, Ferreira ST.

Alzheimers Dement · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/alz.14034

Bibliografisk träff 2024-04-19

Effects of (2R,6R)-hydroxynorketamine in assays of acute pain-stimulated and pain-depressed behaviors in mice.

Hillhouse TM, Partridge KJ, Garrett PI, Honeycutt SC, Porter JH.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0301848

Bibliografisk träff 2024-01-26

Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.

Yamagishi A, Ikekubo Y, Mishina M, Ikeda K, Ide S.

J Pharmacol Sci · journal article · DOI 10.1016/j.jphs.2024.01.008

Bibliografisk träff 2023-10-19

The potent analgesia of intrathecal 2R, 6R-HNK via TRPA1 inhibition in LF-PENS-induced chronic primary pain model.

Liu AR, Lin ZJ, Wei M, Tang Y, Zhang H, Peng XG, Li Y, Zheng YF, Tan Z, Zhou LJ, Feng X.

J Headache Pain · research-article; journal article · DOI 10.1186/s10194-023-01667-1

Bibliografisk träff 2023-10-05

The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement.

Drinkuth CR, Lehane MJ, Sartor GC.

Drug Alcohol Depend · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.drugalcdep.2023.110987

Bibliografisk träff 2023-09-01

Ketamine metabolite alleviates morphine withdrawal-induced anxiety via modulating nucleus accumbens parvalbumin neurons in male mice.

Chen Y, Yan P, Wei S, Zhu Y, Lai J, Zhou Q.

Neurobiol Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.nbd.2023.106279

Bibliografisk träff 2023-08-26

Mechanism of Antidepressant Action of (2R,6R)-6-Hydroxynorketamine (HNK) and Its Compounds: Insights from Proteomic Analysis.

Zhen C, Wang C, Ma Y, Pang Y, Cai F, Meng J, He Y, Xiao P, Liu J, Mei X, Li S, Wu G, Jin G, Zheng B, Liang R, Tan Z.

Mol Neurobiol · journal article · DOI 10.1007/s12035-023-03555-w

Bibliografisk träff 2023-06-15

A Pharmacological Evaluation of the Analgesic Effect and Hippocampal Protein Modulation of the Ketamine Metabolite (2R,6R)-Hydroxynorketamine in Murine Pain Models.

Das V, Basovich MB, Thomas CJ, Kroin JS, Buvanendran A, McCarthy RJ.

Anesth Analg · research-article; journal article; research support, n.i.h., extramural · DOI 10.1213/ane.0000000000006590

Bibliografisk träff 2023-05-01

(2R,6R)-hydroxynorketamine improves PTSD-associated behaviors and structural plasticity via modulating BDNF-mTOR signaling in the nucleus accumbens.

Gou L, Li Y, Liu S, Sang H, Lan J, Chen J, Wang L, Li C, Lian B, Zhang X, Sun H, Sun L.

J Affect Disord · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jad.2023.04.101

Bibliografisk träff 2023-04-02

TRKB interaction with PSD95 is associated with latency of fluoxetine and 2R,6R-hydroxynorketamine.

Fred SM, Moliner R, Antila H, Engelhardt KA, Schlüter OM, Casarotto PC, Castrén E.

Eur J Neurosci · research support, non-u.s. gov't; journal article · DOI 10.1111/ejn.15952

Bibliografisk träff 2023-03-30

(2R,6R)-Hydroxynorketamine Treatment of Rats Exposed to Repetitive Low-Level Blast Injury.

Garcia GP, Perez GM, Gasperi R, Sosa MAG, Otero-Pagan A, Abutarboush R, Kawoos U, Statz JK, Patterson J, Zhu CW, Hof PR, Cook DG, Ahlers ST, Elder GA.

Neurotrauma Rep · research-article; journal article · DOI 10.1089/neur.2022.0088

Bibliografisk träff 2022-12-21

(2R,6R)-hydroxynorketamine targeting the basolateral amygdala regulates fear memory.

Xu Y, Yu Z, Chen S, Li Z, Long X, Chen M, Lee CS, Peng HY, Lin TB, Hsieh MC, Lai CY, Chou D.

Neuropharmacology · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuropharm.2022.109402

Bibliografisk träff 2022-11-30

Intranasal (2R, 6R)-hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice.

Goswami N, Aleem M, Manda K.

Clin Exp Pharmacol Physiol · research support, non-u.s. gov't; journal article · DOI 10.1111/1440-1681.13737

Bibliografisk träff 2022-10-02

(2R,6R)-hydroxynorketamine (HNK) reverses mechanical hypersensitivity in a model of localized inflammatory pain.

Yost JG, Browne CA, Lucki I.

Neuropharmacology · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.neuropharm.2022.109276

Bibliografisk träff 2022-09-13

Comments to behavioral tests for antidepressant-like actions of (2R,6R)-hydroxynorketamine by Bonaventura et al.

Chang L, Hashimoto K.

Mol Psychiatry · letter; comment; research support, non-u.s. gov't · DOI 10.1038/s41380-022-01766-6

Bibliografisk träff 2022-06-29

Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.

Bonaventura J, Gomez JL, Carlton ML, Lam S, Sanchez-Soto M, Morris PJ, Moaddel R, Kang HJ, Zanos P, Gould TD, Thomas CJ, Sibley DR, Zarate CA, Michaelides M.

Mol Psychiatry · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s41380-022-01673-w